Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
The method involves detailed molecular simulations of the receptor in its native membrane environment, with ensemble virtual screening focusing on its conformational mobility. When dealing with dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets on and between the subunits are established to address all possible mechanisms of action.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P42262
UPID:
GRIA2_HUMAN
Alternative names:
AMPA-selective glutamate receptor 2; GluR-B; GluR-K2; Glutamate receptor ionotropic, AMPA 2
Alternative UPACC:
P42262; A8MT92; I6L997; Q96FP6
Background:
Glutamate receptor 2, also known as AMPA-selective glutamate receptor 2, GluR-B, GluR-K2, and Glutamate receptor ionotropic, AMPA 2, is a key receptor for glutamate, facilitating excitatory synaptic transmission in the central nervous system. It transforms chemical signals into electrical impulses, playing a pivotal role in neural communication.
Therapeutic significance:
The protein is implicated in Neurodevelopmental disorder with language impairment and behavioral abnormalities (NEDLIB), where genetic variations affect its function. Understanding the role of Glutamate receptor 2 could open doors to potential therapeutic strategies for treating such neurodevelopmental disorders.